Luchtbrug Junior: the Next Step
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Jan 3, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Luchtbrug Junior trial is studying a new online tool designed to help manage asthma in young children aged 2 to 6 years who experience wheezing. This study aims to see if using this online platform can increase the number of symptom-free days for children while reducing the number of visits to the doctor's office by half. Children will be divided into two groups: one will receive regular care with in-person visits every three months, while the other will use the Luchtbrug Junior tool, which allows for more frequent online check-ins and support from healthcare providers.
To be eligible for this trial, children must be diagnosed with preschool wheeze and have a history of respiratory issues, such as multiple episodes of wheezing or hospital admissions related to breathing problems. Parents or caregivers will need to provide consent for their child to participate. Throughout the study, families can expect regular communication with their healthcare team, feedback on their child's progress, and support to help manage symptoms effectively. This trial is a great opportunity to explore how digital health tools can improve asthma care for young children.
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • Children aged 2 to 6 years with a doctor's diagnosis of preschool wheeze
- • Children have an indication for regular follow-up of at least one year by a paediatrician because of respiratory symptoms;
- • Children are treated with inhaler medication, including inhaled corticosteroids;
- * A history of three episodes of wheezing managed by a healthcare professional of which at least one was observed by a paediatrician in the last 12 months prior to the study, or:
- • At least one hospital admissions due to pulmonary symptoms before inclusion.
- • Informed consent of parents/caregivers
- • Exclusion criteria
- • Underlying chronic cardiopulmonary or neuromuscular condition, or known recurrent aspirations;
- • Underlying syndromes associated with pulmonary comorbidities;
- • Prematurity \<36 weeks after gestation;
- • Inability of parents/caregivers/caretakers to understand and/or read Dutch;
- • No access to a smartphone and/or internet.
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Lara van den Wijngaart, MD, PhD
Principal Investigator
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials